Positron Stock

Positron EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Positron (POSC) as of Aug 1, 2026 is -10.67.

EV/EBIT

-10.67

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Positron is 2026 -10.67 . EV/EBIT (Enterprise Value to EBIT) of Positron was 2025 - . It decreases by % lower compared to the previous year.

The Positron EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2007
0.00 base
Jan 1, 2008
0.00 base
Jan 1, 2009
0.00 base
Jan 1, 2010
0.00 base
Jan 1, 2011
0.00 base
Jan 1, 2012
0.00 base
Jan 1, 2013
0.00 base
Jan 1, 2014
0.00 base
YEARPRICE-TO-EBIT
2014 -
2013 -
2012 -
2011 -
2010 -
2009 -
2008 -
2007 -
2006 -
2005 -
2004 -
2003 -
2002 -
2001 -
2000 -
1999 -
1998 -
1997 -
1996 -
1995 -
Access this data via the Eulerpool API
Get Free API Key

Positron Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Positron's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Positron's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Positron's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Positron grows earnings faster than its peers.

Positron Stock analysis

What does Positron do? Positron Corp is a company in the medical technology industry specializing in the development of PET (positron emission tomography) systems and solutions. The company was founded in 1983 as Positron Corporation with headquarters in Houston, Texas, USA. Initially focused on research and development of technologies for radiation therapy, the company shifted its focus to PET imaging and became a pioneer in the field. Positron Corp's business model is based on selling PET systems and related solutions and services to medical facilities and organizations. The company offers both stationary and mobile systems for various applications such as cancer diagnostics. Positron Corp is divided into different divisions specializing in different areas of PET technology, including the development, production, and distribution of PET modules, systems, and software solutions. The flagship product of Positron Corp is the Total-body PET module, which enables complete imaging of the human body and is unique in the medical field. The module was designed to meet the need for whole-body imaging in cancer diagnostics and offers patients a non-invasive way to monitor cancer cells and metastases. In addition to the Total-body PET module, the company also offers specialized solutions for various areas of PET imaging, including a portable PET scanner suitable for use in emergency rooms or intensive care units. Another area of Positron Corp is the development and production of radiation therapy products. The company has developed a range of radiopharmaceuticals that can be used in cancer treatment, including radioisotopes such as fluorine-18, used for labeling molecules in cancer diagnostics, and yttrium-90, used in radiation therapy for the treatment of liver tumors. To ensure that its products remain at the forefront of technology, Positron Corp is heavily involved in research and development. The company collaborates closely with leading research and development companies to develop innovative solutions and technologies that meet the demands of the medical technology industry. Overall, Positron Corp has established itself as a key player in the medical technology industry, developing innovative solutions and technologies for PET imaging and radiation therapy. The company is committed to improving the standard of medical diagnostics and treatment, contributing to the improvement of healthcare. Positron is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Positron stock

EV/EBIT (Enterprise Value to EBIT) of Positron is -10.67 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Positron

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Positron